3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pain
14
Multiple Myeloma
12
Pain, Postoperative
9
Neoplasms
9
Agnosia
8
Lymphoma, Non-Hodgkin
6
Lung Neoplasms
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
5
Cancer Pain
5
Neoplasm Metastasis
4
Lymphoma
4
Leukemia
4
Hodgkin Disease
4
Head and Neck Neoplasms
4
Burkitt Lymphoma
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Lymphoma, B-Cell
3
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
3
Leukemia, Hairy Cell
3
Hematologic Neoplasms
3
Colonic Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Trigger Finger Disorder
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Philadelphia Chromosome
2
Myelodysplastic Syndromes
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Interventions
Cisplatin
160
Fluorouracil
134
Paclitaxel
125
Radiotherapy
117
Oxaliplatin
87
Carboplatin
71
Docetaxel
70
Irinotecan
59
pembrolizumab
57
Capecitabine
57
Leucovorin
56
Radiation
47
Surgical Procedures, Operative
33
Drug Therapy
33
Esophagectomy
31
Cetuximab
25
Neoadjuvant Therapy
24
Nivolumab
23
Bevacizumab
21
Trastuzumab
20
camrelizumab
19
S 1 (combination)
19
Chemoradiotherapy
17
Albumin-Bound Paclitaxel
16
Magnetic Resonance Spectroscopy
15
Epirubicin
15
tislelizumab
14
Taxes
13
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Neoplasms
×
Acetaminophen
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled